Bank of America
VIRX

Bank of America’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bank of America’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,124
Closed -$180 – 8700
2024
Q4 		$180 Sell
1,124
-13,930
-93% -$2.74K ﹤0.01% 7614
2024
Q3 		$3.48K Buy
15,054
+2,558
+20% +$938 ﹤0.01% 7069
2024
Q2 		$6.79K Buy
12,496
+225
+2% +$177 ﹤0.01% 6962
2024
Q1 		$12.5K Buy
12,271
+4,207
+52% +$3.07K ﹤0.01% 6841
2023
Q4 		$4.6K Sell
8,064
-3,938
-33% -$2.42K ﹤0.01% 7025
2023
Q3 		$12.5K Sell
12,002
-6,036
-33% -$8.19K ﹤0.01% 6809
2023
Q2 		$25.4K Sell
18,038
-5,203
-22% -$7.44K ﹤0.01% 6651
2023
Q1 		$37K Buy
23,241
+10,422
+81% +$18.9K ﹤0.01% 6588
2022
Q4 		$18.7K Sell
12,819
-2,909
-18% -$8.5K ﹤0.01% 6761
2022
Q3 		$67K Buy
15,728
+2,698
+21% +$11.4K ﹤0.01% 6546
2022
Q2 		$50K Sell
13,030
-18,442
-59% -$52.5K ﹤0.01% 6830
2022
Q1 		$149K Sell
31,472
-34,836
-53% -$105K ﹤0.01% 6636
2021
Q4 		$242K Buy
66,308
+12,402
+23% +$66.2K ﹤0.01% 6394
2021
Q3 		$432K Sell
53,906
-2,983
-5% -$29.4K ﹤0.01% 5767
2021
Q2 		$645K Buy
56,889
+53,662
+1,663% +$538K ﹤0.01% 5237
2021
Q1 		$30K Buy
3,227
+2,655
+464% +$27.7K ﹤0.01% 6783
2020
Q4 		$4K Hold
572
– – ﹤0.01% 6869
2020
Q3 		$3K Hold
572
– – ﹤0.01% 6671
2020
Q2 		$5K Sell
572
-1
-0.2% -$15 ﹤0.01% 6570
2020
Q1 		$8K Hold
573
– – ﹤0.01% 6426
2019
Q4 		$7K Sell
573
-26
-4% -$435 ﹤0.01% 6712
2019
Q3 		$15K Buy
599
+26
+5% +$750 ﹤0.01% 6642
2019
Q2 		$15K Hold
573
– – ﹤0.01% 6641
2019
Q1 		$24K Buy
573
+571
+28,550% +$12.9K ﹤0.01% 6451
2018
Q4 		$0 Sell
2
-86
-98% -$3.51K ﹤0.01% 7443
2018
Q3 		$6K Buy
88
+86
+4,300% +$6.53K ﹤0.01% 6792
2018
Q2 		$0 Sell
2
-28
-93% -$2.49K ﹤0.01% 7376
2018
Q1 		$3K Sell
30
-95
-76% -$16.3K ﹤0.01% 6858
2017
Q4 		$17K Hold
125
– – ﹤0.01% 6470
2017
Q3 		$9K Hold
125
– – ﹤0.01% 6587
2017
Q2 		$12K Hold
125
– – ﹤0.01% 6383
2017
Q1 		$18K Buy
125
+96
+331% +$13.7K ﹤0.01% 6353
2016
Q4 		$4K Buy
+29
New +$4.04K ﹤0.01% 6754
2016
Q3 		– Sell
-1
Closed – – 7411
2016
Q2 		$0 Sell
1
-51
-98% -$5.65K ﹤0.01% 7443
2016
Q1 		$6K Hold
52
– – ﹤0.01% 6538
2015
Q4 		$10K Buy
52
+23
+79% +$4.3K ﹤0.01% 6691
2015
Q3 		$5K Sell
29
-6
-17% -$2.17K ﹤0.01% 6760
2015
Q2 		$22K Buy
35
+6
+21% +$3.19K ﹤0.01% 6302
2015
Q1 		$15K Sell
29
-354
-92% -$179K ﹤0.01% 6166
2014
Q4 		$205K Buy
383
+357
+1,373% +$161K ﹤0.01% 5351
2014
Q3 		$39K Buy
26
+2
+8% +$2.9K ﹤0.01% 6676
2014
Q2 		$33K Buy
24
+2
+9% +$2.32K ﹤0.01% 6918
2014
Q1 		$31K Buy
22
+1
+5% +$1.16K ﹤0.01% 6701
2013
Q4 		$22K Buy
21
+8
+62% +$8.27K ﹤0.01% 6987
2013
Q3 		$13K Sell
13
-4
-24% -$4.27K ﹤0.01% 7077
2013
Q2 		$19K Buy
+17
New +$18.9K ﹤0.01% 6982

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Bank of America's VIRX Position: Q1 2025 in Review

Bank of America sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 1,124 shares — an estimated $180 sold.

Bank of America first reported a position in VIRX in Q2 2013 and held it in 46 quarters. The position peaked at $645K in Q2 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Bank of America reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Bank of America sold 1,124 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $180.
  • Bank of America first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 46 quarters.
  • Bank of America's Viracta Therapeutics, Inc. Common Stock position peaked at $645K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.